Author

B. Evers

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:genetic perturbation / CRISPR· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

R. Beijersbergen· 2 shared R. Bernards· 2 shared A. Houtsmuller· 1 shared A. Raams· 1 shared A. Ray Chaudhuri· 1 shared A. Theil· 1 shared B. Geverts· 1 shared B. Morris· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

R. Beijersbergen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A fluorescence-based sensor screen identifies MED12 as a potential microsatellite instability regulator in colon cancer

J. M. Fernandes Neto, S. Venkatesan, M. Dias, C. Lieftink, B. Morris, K. Bresser, L. Vecchione, B. Evers, F. Scheeren, T. Shumacher, R. Beijersbergen, R. Bernards

bioRxiv · Aug 17, 2023 · PreprintCancer Biology

Elongation factor ELOF1 drives transcription-coupled repair and prevents genome instability

M. Geijer, D. Zhou, K. Selvam, B. Steurer, B. Evers, C. Mukherjee, S. Cugusi, M. van Toorn, M. van der Woude, W. Gong, R. Janssens, A. Raams, J. Lebbink, B. Geverts, D. Plummer, , J. Marteijn

This study identifies ELOF1 as a factor that promotes transcription-coupled repair and prevents genome instability by modulating transcription and recruiting repair factors.

bioRxiv · May 11, 2021Cell Biology

phospho-ERK is a response biomarker to a combination of sorafenib and MEK inhibition in liver cancer

R. R. Bernards, C. Wang, H. Jin, D. Gao, B. Evers, G. Jin, Z. Xue, L. Wang, R. Beijersbergen, W.-X. Qin

This study identifies phospho-ERK as a biomarker for response to sorafenib and MEK inhibition in liver cancer, showing synergistic effects in tumors with high phospho-ERK levels.

bioRxiv · Jan 23, 2018Cancer Biology